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A B S T R A CT  
An acute respiratory disease is rampantly spreading in population worldwide caused by a novel 
coronavirus (SARS-CoV-2, also known as COVID-19). The COVID-19 is a major source of disaster 
in the 21thcentury. It has spread throughout China and is received as a pandemic worldwide. Till date 
(18thMay, 2020), a total of 4,827,272patients are infected and more than 3,17,174confirmed deaths have 
been reported with 6.57% fatality rate. Several research investigations have identified that COVID-19 
belongs to β-coronavirus family and has a highly identical genomic structure to bat coronavirus. The 
novel coronavirus uses the same receptor, ACE-2 (angiotensin-converting enzyme 2) as that for SARS-
CoV, and mainly spreads through the respiratory tract. As per WHO, symptoms include shortness of 
breath especially in the lower respiratory tract, sore, throat, cough, headaches and fever. However, the 
specific drugs required to prevent/treat an attack is a major need at this current point of time. In this 
regard, we conducted a systematic review on coronavirus to cover the molecular mechanism of viral 
entry and replication, which provides the basis of future management of COVID-19. 
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1 Introduction  
Coronaviruses is a constitutant of the subfamily Orthocoronavirinae (subgenussarbecovirus), which 
causes diseases in mammals and birds (1). Coronavirus word is derived from Latin word corona, means 
“crown”.  Other members of this family are Coronaviridae, Nidovirales, and realm Riboviria (2). In human they 
cause respiratory tract infections that can be mild, but COVID-19, SARS and MERS can be lethal, if 
immune system is not working strongly (3). Symptoms of COVID-19 are shortness of breath, sore throat, 
cough, headaches, and fever. According to the Centers for Disease Control and Prevention (CDC), 
coronavirus occasionally cause complications in the lower respiratory tract. The infected droplets can spread 
up to 1-2 meter and deposit on surfaces. The virus can remain live on hard surfaces for days in favourable 
conditions. Infection can be spread by inhalation of infected droplets (aerosolization/fecooral route) of 
virus or touching contaminated surfaces. The virus is also present in the stool and contaminated water (68). 
Virus can be destroyed in a minute by common disinfectants like sodium hypochlorite, hydrogen peroxide, 
70% ethanol or even methanol etc(4). Therefore, washing your hands frequently with soap or detergents, 
especially after contact with infected person or environment is advised. 
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In 1930, Coronavirus were first discovered in avian with an acute respiratory infection in chickens 
(5). In 1960 human Coronaviruses were discovered as common cold virus and later named as human 
coronavirus 229Eandhuman coronavirus OC43(6). Other human coronaviruses have been involved in 
serious respiratory tract infections including SARS-CoV in 2003, HCoV NL63in 2004, HKU1 in 2005, 
MERS-CoV in 2012, andCOVID-19in 2019. Noble Coronavirus (COVID-19) first appeared in China, 
Wuhan and officially declared in December 2019, initially named 2019-nCoV by World Health 
Organization (WHO), January 2020.Now, COVID-19 has become a pandemic worldwide. WHO officially 
declared the COVID-19 epidemic as a public health emergency of international concern (7).Chinese 
scientists isolated a COVID-19 from a patient on 7th January 2020 and came out with the genome 
sequencing of the COVID-19(8). The Wuhan strain has been identified as a new strain ofβ-coronavirus 
(Refer figure 3) and has 70% genetic similarity with SARS-CoV. The virus has a 96% similarity to a bat 
coronavirus, so it is widely suspected to have been originated from the bat as well (8, 9, 10).  
As of 18thMay 2020, a total 4,827,272patientshave been infected, while roughly 1,68,532 have 
recovered and 3,17,174have been confirmed dead in the coronavirus pandemic (70). The COVID-19 
epidemic has reached nearly 213 countries(11). The pandemic has resulted in travel restrictions and 
nationwide lockdowns in several countries. Table 1 shows the mostinfectedcountrieswithCOVID-19. 
Table1: Coronavirus cases and deaths country wise (Data as on 18th May 2020). 
S. No Country Confirmed Cases Deaths Fatality rate 
Worldwide  4,827, 272 3,17,174 6.57% 
1.  USA 1,528,179 90,988 5.95% 
2.  Russia 2,90,678 2,722 1.26% 
3.  Spain 2,77,719 27,650 9.95% 
4.  UK 2,43,695 34,636 14.21% 
5.  Brazil 2,42,313 16,192 6.68% 
6.  Italy 2,25,435 31,908 14.15% 
7.  France 1,79,569 28,108 1.56% 
8.  Germany  1,76788 8,052 4.55% 
9.  Turkey 1,49,435 4,140 2.77% 
10.  Iran 1,22,492 7,057 5.76% 
11.  India 96,169 3,029 3.14% 
 
The COVID-19 caused by the coronavirus is a β-coronavirus with enveloped non-segmented positive-
sense RNA (12). They are classified into three groups, based on antigenic spike (S), membrane (M) 
andnucleocapsid (N) proteins. Coronaviruses (CoV) are divided into four genera, including alpha (α), beta 
(β), gamma (γ) and delta (δ). α and β coronaviruses (Refer figure 3) are able to infect mammals, while γ and 
δ coronavirus infect only avian species. In humans, from commonly known seven coronaviruses which 
cause disease, four including 229E, OC43, NL63 and HKU1 have mild effect. Three of the coronaviruses 
can be lethal for humans as SARS (severe acute respiratory syndrome) which emerged in late 2002 and 
disappeared by 2004; MERS (Middle East respiratory syndrome), which emerged in 2012 and remains in 
circulation in camels; and COVID-19, which emerged in December 2019 from China and a global effort is 
under way to contain its spread (7). 
2 Genomic Organization of Coronaviruses 
Coronaviruses are enveloped virus consisting of a lipid bilayer membrane, enveloped and spike 
structural proteins (13), with a positive-sense single-stranded RNA genome and a nucleocapsid of helical 
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structure (2,14). This structure helps to protect the virus when it is outside the host cell (14) as shown in 
Figure 1(a) (69). It also has a shorter spike-like surface protein called hemagglutinin esterase (HE) (10). 
Coronaviruses consist one of the largest genome size of 27 to 34kilo bases in the RNA virus family (15). 




Figure 1. (a). Structure of coronavirus (69) (b). Transmission electron microscopy imaging of COVID-19 (71) 
Figure1(b) shows, the first image of COVID-19 from Indian Council of Medical Research (ICMR, India) 
captured through Transmission Electron Microscopy (TEM) (71). The sample was taken from the throat 
swab of the first laboratory confirmed patient on 30th January 2020 in Kerala, India. Image shows the round 
shape of the virus as well as projections or stalks jutting out from the surface of the novel coronavirus 
particles. 
 
Figure 2. Genomic organization of COVID-19 (3). 
The genome of coronavirus consists5′-leader-UTR transcriptase-spike (S)-envelope, (E)-membrane, 
(M)-nucleocapsid, (N)-3′UTR and poly (A) tail. ORF1a and ORF1b are the open reading frames, cover the 
two-thirds of the whole genome and produce the two viral replicase proteins (polyproteins) (16). Both 
ORFs encode total 16 Non-Structural Proteins (NSPs) which are highly conserved in the coronaviruses. 
These NSPs actively participate to produce replicase transcriptase complex. Transcriptase polyprotein has 
the ability to self-cleave to form non-structural proteins (3) (Refer figure 2). 
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The S protein is heavily glycosylated protein, mainly contains the S1 and S2 subunits. These S subunit 
proteins are processed by host proteases (17). The S1 subunit is responsible for receptor binding and S2 
subunit for membrane fusion. Coronavirus consist two subunits within the S1 unit, which are capable of 
binding to host receptors. One is an amino (N)-terminal domain (NTD) and another is a carboxy (C)-
terminal domain (CTD), are protein receptors for COVID-19 and MERS-CoV (18,29). However, S protein 
in other CoVs as SARS-CoV remains intact on viral particles and only gets cleaved inside endocytic vesicles 
during viral entry (20,21). The M protein (25-30kDa) is the most abundant structural protein in the virion 
structure and has 3 trans- membrane domains that give the virion its shape (22). M protein has a small N-
terminal glycosylated ectodomain and a much larger C-terminal endodomain that extends 6-8 nm into the 
viral particle (23).  
The E protein with small portion about 8-12 kDa are highly divergent (22,24) (Refer figure 2). E protein 
of virion has very limited data suggesting that it is a trans-membrane protein with an N-terminal 
ectodomain, a C-terminal endodomain and has ion channel activity. The ion channel activity in COVID-
19 is required for pathogenesis. Studies suggested that E protein of corona virus is not always lethal 
although depends upon virus type (25). This protein facilitates assembly and release of the virus. N protein 
present in the nucleocapsid of virus has two domains an N-terminal domain (NTD) and a C-terminal 
domain (CTD) which helps RNA binding in-vitro (26). N protein also binds NSP3 (Non-Structural 
Protein3, a key component of the replicase complex) (27,28), and the M protein (29). These proteins help 
together the viral genome to form the Replicase Transcriptase Complex (RTC), and subsequently package 
the encapsulated genome into viral particles. Recent studies suggest that the mutation in NSP2 and NSP3 
play a role in infectious capability and differentiation mechanism of COVID-19 (30). 
3 Action of Mechanism of COVID-19 
3.1 Entry of virion into the Host Cell 
In early phase of infection, COVID-19 attaches to host cell with the viral spike with (S proteins) 
glycoprotein Receptor Binding Domain (RBD). As attachment occurs, virus releases protease to cleave host 
cell and activates the receptor-attached spike protein or S protein receptor interaction. A recent study 
published in Science showed that COVID-19 S protein has higher affinity to ACE2 (Angiotensin-
Converting Enzyme 2) than SARS-CoV S protein (31). ACE2 is anenzymemostly found on the outer cell 
membranes in the lower respiratory tract, lungs, arteries, heart, kidney, and intestines of humans 
(32,33,34).Studies showed that β-CoV receptors have a good capacity to bind with the human cells 
expressing ACE2, dipeptidyl peptidase-4 (DPP4, also known as CD26) or APN (Amino Peptidase N) 
(35,36). The S1 domain of S protein (Refer figure 2), mediates binding to the cognate host cell receptor; 
while, the other S2 domain mediates the fusion events, between viral membrane and host cell membrane, 
that are required for entry of virus into host cells (37).Depending upon host cell protease and membrane 
nature, cleavage and activation allows thevirus to enterthe host cell byendocytosis. Studies suggest that 
many coronaviruses utilize peptidases as their cellular receptor but exact mechanism is still unknown (37,9). 
It is unclear how many of α-coronaviruses utilize aminopeptidase N (APN) as their receptor. Where a 
SARS-CoV (β-coronaviruses) and HCoV-NL63 (α-coronaviruses) use ACE2 as their receptor, MHV enters 
through CEACAM1 receptor and MERS-CoV binds to dipeptidyl-peptidase 4 (DPP4) to gain entry into 
human cells (9) (Refer figure 3).  
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Figure 3. Flow chart showing α and β coronaviruse and their associated receptors;  APNaminopeptidaseN, 
ACE2angiotensin-converting enzyme 2,mCEACAM murine carcinoembryonic antigen-related 
adhesionmolecule 1,DPP4dipeptidyl peptidase 4,HCoVhuman coronavirus,TGEVtransmissible gastroenteritis 
virus ,PED Vporcine epidemic diarrhea virus, FIPV feline infectious peritonitis virus, CCoV canine coronavirus, 
MHV murine hepatitis virus, BCoV bovine coronavirus, SARS-CoV severe acute respiratory syndrome 
coronavirus, MERS-CoV Middle East respiratory syndrome coronavirus (9). 
3.2 Viral genome replication and assembly  
Fusion of viral envelope with host cell membrane results in the release of the viral genome into the 
cytoplasm. The viral genome uses replicase-transcriptase protein RNA dependent RNA polymerase (RdRp) 
to replication and transcription of RNA from a RNA strand (1,37). Viral RNA genome has 5′ methylated 
cap and a3′ polyadenylated tail bind to the host cell's ribosome for translation. Initially the viral genome 
also translates with host ribosome genome at the overlapping open reading frame and form long 
polyprotein. Mature polyproteins have own proteases to cleave the polyprotein into multiple nonstructural 
proteins (9). The replicase of viral genome encodes two large polyproteins (pp1a and pp1b), which encode 
non-structural protein (17) and form replication-transcription complex (RTC) in double-membrane vesicle 
(38). Continuously replications of RTC produce a nested set of sub genomic RNAs (39). Further, these 
RNAs encode accessory proteins and structural proteins. Once sufficient amount of structural proteins and 
viral RNA are formed, viral RNA then assembles with the viral structural proteins into virion. Now, viral 
assembly and budding occur in smooth walled vesicles in the endoplasmic reticulum, Golgi intermediate 
compartment (ERGIC) (40), and virion-containing vesicles fuse with the plasma membrane to release the 
virus through exocytosis, as shown in figure 4. 
Protein-protein instruction via M protein plays an important role in virus assembly, but this is not 
enough for virus-like particles (VLPs) formation. M protein formed VLPs along with E protein. Also, these 
two proteins function together to produce coronavirus envelopes (41). Some literatures suggested that E 
protein prevents the aggregation of M protein (42,43), while others reported that E protein have role in 
promoting viral release by altering the host secretary pathway (44). Non-structural proteins (N) enhance 
the VLP formation and genomes encapsidation. S protein is not required for assembly but to traffic to the 
golgi intermediate compartment and interact with the M protein (41,42). It is still not clear either virus uses 
the traditional pathway for transport of large cargo from the golgi or has a separate, unique pathway for its 
own exit.  
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Figure 4. Life cycle of a COVID-19 
4 Discussion  
Novel coronavirus, COVID-19, was identified In January 2020 as the cause of an outbreak of viral 
pneumonia in Wuhan, China and spread worldwide (45,46). The Centers for Disease Control and 
Prevention (CDCP) and National Institute of Allergy and Infectious Diseases (NIAID) developed a test to 
diagnose COVID-19 in respiratory and serum samples. Earlier NIAID build on research on severe acute 
respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), which were also caused by 
coronaviruses. In above section, Introduction already descried the information about COVID- 
19 (7,12). ICTV-CSG- International Committee on Taxonomy of Viruses- Coronavirus Study Group 
Figure 5. Flow chart showing systematic link between SARS-CoV, MERS-CoV, and COVID-19 (46). 
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Middle East respiratory syndrome (MERS-Cov), caused by the β-coronavirus, is a common-cold 
coronavirus with single-stranded RNA genomic structure (47). MERS-Cov was first reported in Saudi 
Arabia in September 2012 and had since spreaded to 27 countries (centers for disease control and 
prevention). MERS-CoV was believed to be originally from bats (48). As per WHO reported, people 
infected with MERS-CoV develop severe respiratory illness, fever, cough and shortness in breath (3,19). 
The humans were typically infected from camels, via direct or indirect contact. Spread between humans, 
typically required a close contact with an infected person. In January 2020, WHO confirmed 2,519 MERS 
cases and 866 deaths, in which 80% have occurred in Saudi Arabia and only two have tested positive for 
MERS-CoV in United States (48).  
Severe acute respiratory syndrome coronavirus (SARS-CoV or SARS-CoV-1) causes severe acute 
respiratory syndrome (SARS) (49,50). SARS-CoV, belongs toβ-coronavirus family, is a single-stranded 
RNA, positive-sense, enveloped virus and mostly infects the epithelial cells within the lungs. Virus uses 
host ACE2 receptor to enter the host cell (Figure 4). It infects humans, bats, and palm civets (51,52). SARS-
CoV was first observed in Asia in February 2003 and subsequently was tracked back to November 2002 
and quickly spread to 26 countries. It effected more than 8,000 people and 774 died. In April 2003, the 
Centers for Disease Control and Prevention (CDC) and National Microbiology Laboratory (NML) 
identified the SARS-CoV genome (53,54).  
Research based studies suggests that both SARS-CoV and MERS-CoV originated from bats, and 
having similar characteristics like COVID-19 (Figure 5). Scientists are trying to determine how COVID-19 
spread from an animal reservoir to people. Coronavirus pandemic of COVID-19 showed many similarities 
with SARS outbreak in 2002. The COVID-19 also has been also identified the similar characteristics with 
SARS-CoV (48,53,54). Strains of SARS-CoV including human coronavirus 229E(HCoV-229E), human 
coronavirus NL63(HCoV-NL63), human coronavirus OC43 (HCoV-OC43), human coronavirus 
HKU1(HCoV-HKU1), Middle East respiratory syndrome-related coronavirus (MERS-CoV), and COVID-
19 (55,56). 
5 Diagnosis and Treatment 
There is no specific antiviral therapeutics/vaccine made till date that specifically target human 
coronaviruses (COVID-19), so treatments are only supportive. Some studies suggested that in-vitro 
interferons (IFNs) are partially effective against coronaviruses (57) including IFN-1, used as potential 
treatment of other positive ssRNA viruses. In-vitro recombinant INFs α and INFs β inhibit the replication 
of both SARS-CoV and MERS-CoV in animal models. Combination of both INFs α and INFs β along 
with other antivirals such as ribavirin can be used to treat patients with SARS or MERS, however, the 
effectiveness of this combination in-vivo requires further evaluation (57,58). 
Vaccine approved for IBV (Infectious bronchitis virus), TGEV (Transmissible gastroenteritis virus), 
porcine epidemic diarrhea virus (PEDV, a vaccine for veterinary pathogens) and Canine CoV can be used 
as to prevent coronavirus infections, but these vaccines are not always used because they are not very 
effective. In some studies, it has been reported that these vaccines are involved in the selection of novel 
pathogenic COVIDs via recombination of circulating strains (59,50). There are several potential vaccines 
which have been developed viz., recombinant attenuated viruses, live virus vectors, or individual viral 
proteins expressed from DNA plasmids, but they are still waiting for approval for diagnosis of SARS-
COVID (61,62). 
Some studies have shown during this pandemic chloroquine (an anti-malarial drug, used to prevent or 
treat malaria) might be effective against COVID-19 (63,64). Researchers and scientists think that 
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chloroquine might help COVID-19 patients by inhibiting the coronavirus from entering the cell.  India, 
USA, Spain and some other countries are widely using this drug prophylactically and have found some 
success in recovery of COVID-19 positive patients. The Danish Medicine Agency has refused to authorize 
Chloroquine for COVID-19. European Medicine Agency has announced that chloroquine should only be 
used for clinical trials (65). At present there are not enough scientific studies to draw any conclusion on the 
effect of Chloroquine drug on COVID-19. 
Now a multiplex real-time RT-PCR assay has become the new choice for diagnosis of human COVID. 
Also, it is able to detect all four respiratory human COVIDs (66,67). RT-PCR is useful to detect the 
conserved RNA sequences of virus, but studies suggest that it needs more attention. Serologic assays are 
important in cases where RNA is difficult to isolate or is no longer stable, and for epidemiological studies. 
The best way to control or protect from this virus is via strong public health surveillance system coupled 
with rapid diagnostic testing and quarantine when necessary. Take healthy food to boost immune system. 
For international outbreaks, cooperation of governmental entities, public health authorities, and health care 
providers is critical. The WHO and other organizations have issued the following general recommendations 
(68). 
• Avoid close contact with infected patients. 
• Wash hands frequently, especially after contact with infected person. 
• Avoid unprotected contact with farm or wild animals. 
• People with symptoms of acute airway infection should keep their distance, cover coughs or sneezes 
with disposable tissues or clothes and wash their hands. 
• Strengthen, in particular, in emergency medicine departments, the application of strict hygiene 
measures for the prevention and control of infections. 
• Individuals that are immune compromised should avoid public gatherings. 
6 Conclusion  
Several research investigations have identified that COVID-19 belongs to β-coronavirus family with 
positive sense RNA genome and has a highly identical genomic structure to bat coronavirus. The 
novelCOVID-19 uses ACE2 (Angiotensin-converting enzyme 2) receptor as a binding receptor for their 
entry to human host cell, and mainly spreads through the respiratory tract. Several protein including S, M 
and E played an important role in virus packaging and assembling. Through a planned endocytosis and 
exocytosis pathway virus easily replicated their life cycle inside the living cell and transmitted to other cell. 
Till date, there is no specific antiviral therapeutics/vaccine made that are specifically target 
human coronaviruses (COVID-19), so treatments are only supportive. Studies suggest that interferon’s 
(IFNs) are partially effective against coronaviruses. Vaccines including IBV, TGEV, PEDV are effective in 
some cases, but are not always used. Some studies have shown during this pandemic chloroquine might be 
effective against COVID-19. Molecular technique RT-PCR might be a useful tool to help to diagnose 
the COVID-19, but still needs more improvement. The outbreak of COVID-19 swept across China rapidly 
and has spread to 213 countries and killed more the 3,17,174 people with 6.57% fatality rate. Research 
studies suggest that both SARS-CoV and MERS-CoV were originated from bats, and have similar 
characteristics like COVID-19. Scientists have made progress in the characterization of the novel 
coronavirus and are working extensively on the therapies and vaccines against COVID-19. Till that, the 
best way to control or protect from this virus is via strong public health surveillance system coupled with 
rapid diagnostic testing and quarantine when necessary.  
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